Compare DSGN & BFK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DSGN | BFK |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.1M | 441.2M |
| IPO Year | 2021 | N/A |
| Metric | DSGN | BFK |
|---|---|---|
| Price | $9.83 | $9.96 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 526.0K | 117.1K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.33% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.60 | $8.55 |
| 52 Week High | $10.02 | $10.48 |
| Indicator | DSGN | BFK |
|---|---|---|
| Relative Strength Index (RSI) | 71.46 | 49.81 |
| Support Level | $8.58 | $9.80 |
| Resistance Level | $9.85 | $9.98 |
| Average True Range (ATR) | 0.67 | 0.09 |
| MACD | 0.14 | 0.00 |
| Stochastic Oscillator | 93.77 | 67.62 |
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
Blackrock Municipal Income Trust is a closed-end municipal bond fund. Its investment objective is to provide current income exempt from regular U.S. federal income tax.